## Amgen's Tavneos Reportedly Linked to 20 Deaths in Japan, Prompting Safety Scrutiny
Amgen's precision medicine drug Tavneos has reportedly been associated with 20 fatalities in Japan, according to regulatory filings and market reports emerging from Seeking Alpha's coverage of pharmaceutical safety signals in the Asian market. The deaths, reported through Japan's Pharmaceuticals and Medical Devices Agency (PMDA) adverse event monitoring system, signal mounting pressure on the U.S. biotech giant as investigators scrutinize whether the drug played a causal role or merely coincided with patient deaths in a population with severe underlying vasculitis conditions.

Tavneos (avacopan), approved in Japan for severe active granulomatosis with polyangiitis and microscopic polyangiitis, represents a key commercial asset for Amgen following its $2.7 billion acquisition of ChemoCentryx in 2022. The drug generates significant revenue in the rare disease space, and any confirmed safety signal could reshape its commercial trajectory across global markets. Sources indicate the reported deaths span several months of post-marketing surveillance, raising questions about whether the drug's complement C5a receptor antagonist mechanism may trigger adverse cardiac or hepatic events in vulnerable patient populations.

The reports place Amgen's pharmacovigilance practices under heightened scrutiny, with investors and analysts monitoring for regulatory actions, label warnings, or market withdrawal risks. While causality remains unestablished and the Japanese patient population presents complex comorbidities, the sheer volume of reported fatalities within a relatively limited prescription base intensifies concerns. Analysts note that any adverse regulatory determination could extend beyond Japan, potentially affecting Tavneos approvals in Europe and additional Asian markets where the drug holds authorization.
---
- **Source**: Seeking Alpha
- **Sector**: The Vault
- **Tags**: pharmaceutical, drug safety, adverse events, Japan regulatory, Amgen Tavneos
- **Credibility**: unverified
- **Published**: 2026-05-16 13:18:28
- **ID**: 83844
- **URL**: https://whisperx.ai/en/intel/83844